Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Clinical Trials Related to Esophageal Squamous Cell Carcinoma
Related studies linked through entity extraction aliases.
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
- Status
- RECRUITING
- Phase
- PHASE3
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
- Status
- RECRUITING
- Phase
- PHASE2
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Status
- RECRUITING
- Phase
- PHASE1
Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- N/A
Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
- Status
- RECRUITING
- Phase
- PHASE2